BICO Group AB (publ) (“BICO” or “the company”) today publishes an adjusted version of its Annual and Sustainability Report 2023 on its website. Adjustments has been made in Annual Report 2023 with regards to BICOs changed method for impairment test of goodwill which resulted in retroactive impairment of goodwill and other immaterial assets.

The adjusted Annual and Sustainability Report 2023 is now available digitally in Swedish and an English language version at https://bico.com/investors/financials/financial-reports-and-presentations/.

A mark-up version is also available to highlight the adjustments made compared to the version of the Annual Report 2023 published as of March 15, 2024. The mark-up version is available via the link above, under the section additional reports.

BICO announced, on May 6, 2024, via a press release that the Company had changed method for impairment test of goodwill, which resulted in retroactive impairment of goodwill and other immaterial assets. The adjustments were therefore published in the next financial report, which was the Q1 2024 interim report published on May 7, 2024. The retroactive impairments in the Q1 2024 interim report leads to adjustments in the 2023 Annual Report and accordingly a new adjusted version is published as of today, which will be submitted for approval at BICO's upcoming Annual General Meeting on May 20, 2024.

The Annual Report in accordance with European Single Electronic Format (ESEF) is available in Swedish.

BICO has for sustainability reasons chosen not to print nor distribute hard copies of the report. Those who are unable to access the report digitally can request a print-out by contacting BICO Investor Relations, ir@bico.com.

For further information, please contact:
Maria Forss, President & CEO, BICO Group AB
Phone: EA Isabella Lundin +46 73 515 99 64
E-mail: mf@bico.com

Jacob Thordenberg, Chief Financial Officer, BICO Group AB
Phone: +46 73 534 88 84
E-mail: jt@bico.com

This information is information that BICO Group is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-05-13 18:00 CEST.

About BICO
BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 46,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 12,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction of the world’s organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

Attachments
BICO Annual Report 2023 EN May 13 2024
bicogroupab-2023-12-31-sv

© Modular Finance, source Nordic Press Releases